Table 5. Secondary Endpoints.
Placebo (n=8,696) |
Vitamin E alone (n=8,737) |
Selenium alone (n=8,752) |
Vitamin E + selenium (n=8,702) |
|
---|---|---|---|---|
Colorectal Cancer | 75 | 85 | 74 | 93 |
Hazard ratio (99% CI) | 1.09 (0.72, 1.64) | 0.96 (0.63, 1.46) | 1.21 (0.81, 1.81) | |
p-value | p=0.60 | p=0.79 | p=0.22 | |
Lung Cancer | 92 | 104 | 94 | 104 |
Hazard ratio (99% CI) | 1.11 (0.76, 1.61) | 1.02 (0.70, 1.50) | 1.11 (0.76, 1.62) | |
p-value | p=0.49 | p=0.89 | p=0.48 | |
All other primary cancers (excludes prostate, includes colorectal and lung) | 579 | 570 | 557 | 594 |
Hazard ratio (99% CI) | 0.97 (0.83, 1.14) | 0.96 (0.83, 1.13) | 1.02 (0.88, 1.19) | |
p-value | p=0.65 | p=0.54 | p=0.74 | |
All cancers (including prostate) | 1108 | 1190 | 1132 | 1149 |
Hazard ratio (99% CI) | 1.07 (0.96, 1.19) | 1.02 (0.92, 1.14) | 1.02 (0.92, 1.14) | |
p-value | p=0.13 | p=0.59 | p=0.60 | |
Deaths (all cause) | 564 | 571 | 551 | 542 |
Hazard ratio (99% CI) | 1.01 (0.86, 1.17) | 0.98 (0.84, 1.14) | 0.96 (0.82, 1.12) | |
p-value | p=.91 | p=.67 | p=.47 | |
October 23, 2008† | ||||
Diabetes* | 669 | 700 | 724 | 660 |
Relative Risk (99% CI) | 1.04 (0.90 – 1.18) | 1.07 (0.94 – 1.22) | 0.97 (0.86 – 1.11) | |
p-value | p = 0.47 | p = 0.16 | p = 0.61 | |
July 5, 2011 | ||||
Diabetes* | 869 | 918 | 913 | 875 |
Relative Risk (99% CI) | 1.05 (0.93 – 1.17) | 1.04 (0.93 – 1.17) | 0.99 (0.89 – 1.12) | |
p-value | p = 0.29 | p = 0.34 | p = 0.91 | |
Cardiovascular events, grade 4 or higher** | 969 | 909 | 939 | 943 |
Hazard Ratio (99% CI) | 0.93 (0.83,1.05) | 0.97 (0.86,1.09) | 0.97 (0.86,1.09) | |
p-value | p = 0.11 | p = 0.45 | p = 0.51 |
Date of data freeze for initial publication
Prevalent cases at baseline and men who never submitted a form with a diabetes assessment are excluded from the analysis.
Time to first reported cardiovascular event, cardiovascular procedure (e.g., CABG), or hemorrhagic stroke, all men. Cardiovascular endpoints were not centrally adjudicated.